On March 15, 2024, Akebia Therapeutics, Inc. and Ellen Snow mutually agreed that she would transition from her role as the Company?s Senior Vice President and Treasurer, effective March 22, 2024. John Butler, the Company?s President and Chief Executive Officer, will act as interim principal financial officer from the Transition Date. Mr. Butler, age 59, has served as a member of the Company?s Board of Directors since July 2013 and was appointed as the President and Chief Executive Officer of the Company in September 2013.

Prior to joining the Company, from 2011 until 2013, Mr. Butler served as the Chief Executive Officer of Inspiration Biopharmaceuticals, Inc. From 1997 to 2011, Mr. Butler held various positions at Genzyme Corporation, now Sanofi Genzyme (?Genzyme?), most recently serving as President of the company?s rare genetic diseases business. From 2002 until 2010, Mr. Butler led Genzyme?s renal division. Prior to his work at Genzyme, Mr. Butler held sales and marketing positions at Amgen Inc. and Hoffmann-La Roche.

From 2018 to October 2023, Mr. Butler served on the board of directors of Zynerba Pharmaceuticals, Inc. From 2013 to 2016, Mr. Butler served on the board of directors of Relypsa, Inc. From 2015 to 2017, Mr. Butler served on the board of directors of Keryx Biopharmaceuticals, Inc. (?Keryx?) and was Chairman of Keryx?s board of directors from 2016 to 2017. Mr. Butler formerly served as Chair of Kidney Care Partners and as a Chairman of the Board of Trustees of the American Kidney Fund. Mr. Butler received a B.A. in chemistry from Manhattan College and an M.B.A. degree from Baruch College, City University of New York.